Literature DB >> 29237681

Plasma Proteomics for Epidemiology: Increasing Throughput With Standard-Flow Rates.

Xiaoke Yin1, Ferheen Baig1, Eloi Haudebourg1, Richard T Blankley1, Tejas Gandhi1, Sebastian Müller1, Lukas Reiter1, Helmut Hinterwirth1, Raimund Pechlaner1, Sotirios Tsimikas1, Peter Santer1, Johann Willeit1, Stefan Kiechl1, Joseph L Witztum1, Anthony Sullivan1, Manuel Mayr2.   

Abstract

BACKGROUND: Mass spectrometry is selective and sensitive, permitting routine quantification of multiple plasma proteins. However, commonly used nanoflow liquid chromatography (LC) approaches hamper sample throughput, reproducibility, and robustness. For this reason, most publications using plasma proteomics to date are small in study size. METHODS AND
RESULTS: Here, we tested a standard-flow LC mass spectrometry (MS) method using multiple reaction monitoring for the application to large epidemiological cohorts. We have reduced the LC-MS run time to almost a third of the nanoflow LC-MS approach. On the basis of a comparison of the quantification of 100 plasma proteins in >1500 LC-MS runs, the SD range of the retention time during continuous operation was substantially lower with the standard-flow LC-MS (<0.05 minutes) compared with the nanoflow LC-MS method (0.26-0.44 minutes). In addition, the standard-flow LC method also offered less variation in protein measurements. However, 5× more sample volume was required to achieve similar sensitivity. Two different commercial multiple reaction monitoring kits and an antibody-based multiplexing kit were used to compare the apolipoprotein measurements in a subset of samples. In general, good agreement was observed between the 2 multiple reaction monitoring kits, but some of the multiple reaction monitoring-based measurements differed from antibody-based assays.
CONCLUSIONS: The multiplexing capability of LC-MS combined with a standard-flow method increases throughput and reduces the costs of large-scale protein measurements in epidemiological cohorts, but protein rather than peptide standards will be required for defined absolute proteoform quantification.
© 2017 The Authors.

Entities:  

Keywords:  apolipoprotein; cardiovascular disease; mass spectrometry; precision medicine; proteomics

Mesh:

Substances:

Year:  2017        PMID: 29237681     DOI: 10.1161/CIRCGENETICS.117.001808

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN: 1942-3268


  7 in total

1.  Mass Spectrometry-Based Plasma Proteomics: Considerations from Sample Collection to Achieving Translational Data.

Authors:  Vera Ignjatovic; Philipp E Geyer; Krishnan K Palaniappan; Jessica E Chaaban; Gilbert S Omenn; Mark S Baker; Eric W Deutsch; Jochen M Schwenk
Journal:  J Proteome Res       Date:  2019-10-11       Impact factor: 4.466

2.  In Aptamers They Trust: The Caveats of the SOMAscan Biomarker Discovery Platform from SomaLogic.

Authors:  Abhishek Joshi; Manuel Mayr
Journal:  Circulation       Date:  2018-11-26       Impact factor: 29.690

3.  Peptide-Spectrum Match Validation with Internal Standards (P-VIS): Internally-Controlled Validation of Mass Spectrometry-Based Peptide Identifications.

Authors:  Timothy Aaron Wiles; Laura M Saba; Thomas Delong
Journal:  J Proteome Res       Date:  2020-09-29       Impact factor: 4.466

4.  Robust, reproducible and quantitative analysis of thousands of proteomes by micro-flow LC-MS/MS.

Authors:  Yangyang Bian; Runsheng Zheng; Florian P Bayer; Cassandra Wong; Yun-Chien Chang; Chen Meng; Daniel P Zolg; Maria Reinecke; Jana Zecha; Svenja Wiechmann; Stephanie Heinzlmeir; Johannes Scherr; Bernhard Hemmer; Mike Baynham; Anne-Claude Gingras; Oleksandr Boychenko; Bernhard Kuster
Journal:  Nat Commun       Date:  2020-01-09       Impact factor: 14.919

5.  Multi-Omic Single-Shot Technology for Integrated Proteome and Lipidome Analysis.

Authors:  Yuchen He; Edrees H Rashan; Vanessa Linke; Evgenia Shishkova; Alexander S Hebert; Adam Jochem; Michael S Westphall; David J Pagliarini; Katherine A Overmyer; Joshua J Coon
Journal:  Anal Chem       Date:  2021-02-22       Impact factor: 6.986

6.  Inhibition of profibrotic microRNA-21 affects platelets and their releasate.

Authors:  Temo Barwari; Seda Eminaga; Ursula Mayr; Ruifang Lu; Paul C Armstrong; Melissa V Chan; Mahnaz Sahraei; Marta Fernández-Fuertes; Thomas Moreau; Javier Barallobre-Barreiro; Marc Lynch; Xiaoke Yin; Christian Schulte; Ferheen Baig; Raimund Pechlaner; Sarah R Langley; Anna Zampetaki; Peter Santer; Martin Weger; Roberto Plasenzotti; Markus Schosserer; Johannes Grillari; Stefan Kiechl; Johann Willeit; Ajay M Shah; Cedric Ghevaert; Timothy D Warner; Carlos Fernández-Hernando; Yajaira Suárez; Manuel Mayr
Journal:  JCI Insight       Date:  2018-11-02

7.  PCSK9 Activity Is Potentiated Through HDL Binding.

Authors:  Sean A Burnap; Katherine Sattler; Raimund Pechlaner; Elisa Duregotti; Ruifang Lu; Konstantinos Theofilatos; Kaloyan Takov; Gerd Heusch; Sotirios Tsimikas; Carlos Fernández-Hernando; Sarah E Berry; Wendy L Hall; Marlene Notdurfter; Gregorio Rungger; Bernhard Paulweber; Johann Willeit; Stefan Kiechl; Bodo Levkau; Manuel Mayr
Journal:  Circ Res       Date:  2021-10-04       Impact factor: 17.367

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.